Back to discover
Disease

Amblyopia

Late-stage therapeutic developmentEmerging research
1
Publications
10
Clinical trials
2024
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Clinical trials

6 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
10
All trials
1
Active
6
Late-stage
6
Completed
Late-stage studies

A Randomized Trial of Levodopa as Treatment for Residual Amblyopia (ATS 17)

Phase 3 · Completed · Jaeb Center for Health Research

Augmenting Atropine Treatment for Amblyopia in Children 3 to < 8 Years Old

Phase 3 · Completed · Jaeb Center for Health Research

An Evaluation of Treatment of Amblyopia in 7 To <18 Year Olds

Phase 3 · Completed · Jaeb Center for Health Research

Amblyopia Treatment Study

Phase 3 · Completed · National Eye Institute (NEI)

A Randomized Trial to Evaluate Combined Patching-Atropine for Residual Amblyopia

Phase 3 · Terminated · Jaeb Center for Health Research
Recently completed

Recovery From Amblyopia With Cholinesterase Inhibitors

Phase 1 · Completed · Boston Children's Hospital

A Randomized Trial of Levodopa as Treatment for Residual Amblyopia (ATS 17)

Phase 3 · Completed · Jaeb Center for Health Research

Augmenting Atropine Treatment for Amblyopia in Children 3 to < 8 Years Old

Phase 3 · Completed · Jaeb Center for Health Research

An Evaluation of Treatment of Amblyopia in 7 To <18 Year Olds

Phase 3 · Completed · Jaeb Center for Health Research

Amblyopia Treatment Study

Phase 3 · Completed · National Eye Institute (NEI)

Research activity

1 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Most influential
Recent publications
Major themes4
  • Amblyopia1
  • Neuronal Plasticity1
  • Vision, Binocular1
  • Visual Acuity1
Leading journals1
  • European journal of ophthalmology1
Leading researchers5
  • Bex P1
  • Concetta Morrone M1
  • Lozama A1
  • Sabel BA1
  • Thompson B1
Affiliations (unnormalised)5
  • Centre for Eye and Vision Science1
  • Institute of Medical Psychology1
  • Northeastern University1
  • University of Pisa1
  • University of Waterloo1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

A nonspecific term referring to impaired vision. Major subcategories include stimulus deprivation-induced amblyopia and toxic amblyopia. Stimulus deprivation-induced amblyopia is a developmental disorder of the visual cortex. A discrepancy between visual information received by the visual cortex from each eye results in abnormal cortical development. STRABISMUS and REFRACTIVE ERRORS may cause this condition. Toxic amblyopia is a disorder of the OPTIC NERVE which is associated with ALCOHOLISM, tobacco SMOKING, and other toxins and as an adverse effect of the use of some medications.

Identifiers
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.